View stay: ECB President Christine Lagarde speaks after amount conclusion

[The stream is slated to start at 8:45 EST. Please refresh the page if you do not see a player above at that time.]

European Central Financial institution President Christine Lagarde is thanks to give a press conference following the bank’s hottest monetary policy conclusion.

The ECB, the central financial institution of the 19 nations that share the euro currency, opted for a smaller charge hike this time about, getting its crucial charge from 1.5% to 2%.

It also explained that from the beginning of March 2023 it would start off to reduce its stability sheet by 15 billion euros ($16 billion) for every month on average till the end of the 2nd quarter of 2023.

Subscribe to CNBC on YouTube.

Resource

Finance

Stocks making the biggest moves after hours: Cisco, Flutter Entertainment, Firefly and more

November 12, 2025

Check out the companies making headlines in after-hours trading. Cisco — Shares of Cisco gained more than 7% in extended trading after the networking company posted better-than-expected profit and revenue for its fiscal first quarter. Cisco earned $1 per share, excluding items, on $14.88 billion in revenue, while analysts polled by LSEG expected 98 cents […]

Finance

Boston Fed President Collins advocates holding rates steady, sees ‘high bar’ for further cuts

November 12, 2025

Key Points Boston Fed President Susan Collins said she will be reluctant to support further rate cuts anytime soon with inflation still high and policymakers hampered by a lack of data. “I see several reasons to have a relatively high bar for additional easing in the near term,” said Collins, a voter this year on […]

Finance

Stocks making the biggest moves midday: Goldman Sachs, AMD, Oklo, Circle Internet & more

November 12, 2025

Check out the companies making the biggest moves midday: Alkermes — The biotech company dropped 9% as traders weighed phase 2 trial results for its ALKS 2680 drug, which aims to treat narcolepsy. While the company will be advancing the drug to a Phase 3 trial, a higher range of doses or a split dosing […]